Paying Off Your Generic Drug Competition? No Problem.
Posted on: Friday, October 31st, 2008 in: UncategorizedThe U.S. Court of Appeals for the Federal Circuit gave a high-five to settlement agreements between a patent holder and a generic manufacturer saying it doesn’t violate antitrust laws under the Hatch-Waxman Act. In re Ciprofloxacin Hydrochloride Antitrust Litigation (08-1097). The agreements in question involved a reverse payment from the Bayer to Barr, but did not involve the 180-day exclusivity period. This is not small change as the payments from Bayer to Barr totaled $398.1 million, whic










